证券代码：300143 证券简称：盈康生命 公告编号：2025-042 盈康生命科技股份有限公司 关于注销募集资金专户的公告 截至本公告披露日，公司本次向特定对象发行股票全部募集资金专项账户的情 况如下： | 开户银行 | 银行账号 | 户名 | 账户状态 | | --- | --- | --- | --- | | 交通银行青岛中山 | 372005562013004245321 | 盈康生命科技股份有限 | 本次注销 | | 路支行 | | 公司 | | 三、本次注销募集资金专项账户情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意盈康生命科技股份有限公司向特定对象 发行股票注册的批复》（证监许可〔2024〕1065号）同意，公司向特定对象青岛盈 康医疗投资有限公司非公开发行人民币普通股（A股）107,897,664股，每股面值为 人民币1元，每股发行价格为人民币8.99元。本次发行募集资金总额为人民币 969,999,999.36元，扣除各项发行费用（不含税）人民币9,610,721.65元后，实 ...

Core Viewpoint - The company emphasizes the importance of shareholder rights and aims to enhance operational performance and intrinsic value to reward investors [1] Financial Performance - In the first half of 2025, the company achieved a revenue of 843 million yuan, representing a year-on-year growth of 2.40% [1] - The net profit attributable to shareholders was 61.83 million yuan, reflecting a year-on-year increase of 12.82% [1] Shareholder Engagement - The company is committed to protecting the rights of minority shareholders through various initiatives, including: 1) Focusing on core business to improve operational quality and efficiency [1] 2) Strengthening value communication to help the market better recognize the company's investment value [1] 3) Enhancing communication through multiple channels to increase interaction [1] 4) Actively researching shareholder return plans [1]

Summary of Key Points Core Viewpoint - On August 27, Yingkang Life executed a block trade of 350,000 shares, amounting to 3.6785 million yuan, which represented 1.05% of the total trading volume for that day, with a transaction price of 10.51 yuan, reflecting a discount of 2.05% compared to the market closing price of 10.73 yuan [1]. Group 1 - The block trade involved 350,000 shares of Yingkang Life [2]. - The total transaction amount for the block trade was 3.6785 million yuan [2]. - The transaction price was set at 10.51 yuan per share, which is lower than the market closing price [1][2].

Core Viewpoint - The company is actively monitoring advancements in the global medical technology sector, particularly the application of brain-computer interface technologies in healthcare settings [1] Group 1: Company Developments - The company’s hospital in Yuncheng has successfully completed 23 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] - The introduction of "directional electrodes" technology addresses the side effects associated with traditional high-frequency stimulation [1] - The hospital has pioneered the "asleep DBS" technique, which reduces intraoperative stress responses and expands the eligibility for elderly patients, positioning itself among the top in surgical volume in Shanxi Province [1] Group 2: Future Directions - The company plans to actively explore the feasibility of advanced brain-computer interface technologies, focusing on neurological rehabilitation and the treatment of complex brain diseases [1] - There is an emphasis on enhancing diagnostic and treatment technologies for neurological disorders such as Alzheimer's disease, post-stroke sequelae, and Parkinson's disease [1]

Core Viewpoint - The company is actively monitoring advancements in global medical technology, particularly the application of brain-computer interface technologies in healthcare settings [1] Group 1: Company Developments - The company’s hospital has successfully completed 23 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] - The introduction of "directional electrodes" technology addresses the side effects associated with traditional high-frequency stimulation [1] - The company has pioneered the "asleep DBS" technique, which reduces intraoperative stress responses and expands the eligibility for elderly patients [1] Group 2: Market Position and Future Plans - The hospital ranks among the top in surgical volume in Shanxi Province, indicating a significant regional impact [1] - The company plans to explore the feasibility of advanced brain-computer interface technologies, focusing on neurological rehabilitation and treatment of complex brain diseases [1] - Future initiatives will aim to enhance diagnostic and treatment technologies for Alzheimer's disease, post-stroke sequelae, and Parkinson's disease [1]

Core Viewpoint - AI-related stocks showed strong performance on August 27, with notable gains in several companies, indicating a positive market sentiment towards the AI sector [1]. Company Performance - Nengke Technology (能科科技) reached a limit-up, marking its second consecutive trading day of gains, with a rise of 10% [2]. - Kute Intelligent (酷特智能) increased by over 8%, reflecting strong investor interest [1]. - Yinkang Life (盈康生命) and Wanxing Technology (万兴科技) also experienced upward movement, contributing to the overall positive trend in AI stocks [1]. - Other companies such as Doushen Education (豆神教育) and Huichan Technology (慧辰股份) also reported gains, with the latter showing a rise of 6.14% [2]. Percentage Changes - Nengke Technology (能科科技) recorded a significant increase of 53.02% in its stock price [2]. - Kute Intelligent (酷特智能) saw a rise of 25.90% [2]. - Yinkang Life (盈康生命) and Wanxing Technology (万兴科技) had increases of 11.27% and 89.88%, respectively [2]. - Doushen Education (豆神教育) experienced a gain of 10.10% [2].

Group 1: Yingkang Life - The company has invested in establishing the Tianjin Tiankai Youda Haihe Baiying Equity Investment Fund Partnership [1] - Yingkang Life's AI platform, Yingkang Brain, integrates with the DeepSeek-R1 large language model for enhanced medical services [1] - The company is upgrading its high-end 3D digital mammography imaging technology through AI image analysis [1] Group 2: Haitong Development - In the first half of 2025, Haitong Development achieved revenue of 1.8 billion, a year-on-year increase of 6.74%, but net profit attributable to shareholders dropped 64% to 87 million due to declining market rates and ship repair impacts [2] - The company plans to expand its fleet to 100 vessels by 2028-2029, adding approximately 15 vessels annually, with a focus on various ship types [2] - Haitong Development maintains an optimistic outlook for the dry bulk market, supported by favorable supply and demand factors, and plans to reinvest retained earnings into fleet expansion while increasing cash dividend ratios in the future [2] Group 3: Minmetals New Energy - The company's second-quarter profitability was driven by improved market conditions and increased production capacity utilization [3] - Minmetals New Energy is collaborating with a professor team from the University of Science and Technology of China on solid-state battery research, focusing on high-nickel materials and halide batteries [3] - The company is primarily applying lithium iron phosphate products in the power battery sector while also developing technology in the energy storage field [3]

Group 1: Rare Earth Industry - The implementation of the "Rare Earth Management Regulations" starting from October 1, 2024, marks the beginning of supply-side reforms in the rare earth sector, with increasingly stringent regulations observed [5] - Continuous price increases for light rare earth elements since July this year, along with the re-evaluation of rare earths as strategic key mineral resources, indicate ongoing upward momentum in the rare earth sector [5] Group 2: China Hongqiao (1378.HK) - In the first half of 2025, China Hongqiao reported a 35% year-on-year increase in net profit attributable to shareholders, supported by declining costs and rising product prices and volumes [5] - The downward trend of the US dollar and sustained industry demand contribute to the resilience of electrolytic aluminum prices [5] - The company's significant share buybacks reflect long-term confidence, while high dividends continue to enhance shareholder returns [5] Group 3: Honglu Steel Structure (002541.SZ) - In the first half of 2025, Honglu Steel Structure achieved revenues of 1.06 billion yuan, a 2% year-on-year increase, but experienced a 33% decline in net profit attributable to shareholders [5] - The second quarter of 2025 saw revenues of 570 million yuan, a 3% year-on-year decrease, with net profit also down by 33% [5] Group 4: Hangcha Group (603298.SH) - Hangcha Group reported a revenue of 9.3 billion yuan in the first half of 2025, an 8.7% year-on-year growth, with a net profit of 1.12 billion yuan, up 11.4% [7] - The gross margin increased by 0.6 percentage points to 22.0%, while the net margin rose by 0.1 percentage points to 12.6% [7] Group 5: Wuxi Zhenhua (605319.SH) - In the first half of 2025, Wuxi Zhenhua's total revenue increased by 15.2% to 1.29 billion yuan, with a net profit growth of 27.2% to 200 million yuan [8] - The second quarter of 2025 saw a revenue increase of 9.5% year-on-year and a net profit increase of 31.9% [8] Group 6: Semir Apparel (002563.SZ) - Semir Apparel's revenue for the first half of 2025 was 6.15 billion yuan, reflecting a 3.3% year-on-year growth, while net profit decreased by 41.2% to 330 million yuan [8] - The company proposed a cash dividend of 0.15 yuan per share, resulting in a payout ratio of 124% for the first half of the year [8] Group 7: YK Life (300143.SZ) - YK Life reported a revenue of 843 million yuan in the first half of 2025, a 2.4% year-on-year increase, with a net profit of 62 million yuan, up 12.82% [8] - The non-recurring net profit attributable to shareholders grew by 19.22% to 61 million yuan, meeting expectations [8]

Group 1 - The core viewpoint is that Yingkang Life emphasizes the steady improvement in the core competitiveness and brand influence of Maxip Medical Technology Development (Shenzhen) Co., Ltd, which is a significant growth driver for the listed company [2] - The company highlights the importance of market value management and investor returns, acknowledging that various factors influence corporate market value [2]

Core Viewpoint - Yingkang Life announced that Changsha Kexin Tumor Hospital Co., Ltd. completed the industrial and commercial registration of equity transfer on May 30, 2025, and will be included in the company's consolidated financial statements, with its revenue and net profit reflected in the semi-annual report as required [1] Group 1 - The equity transfer of Changsha Kexin Tumor Hospital Co., Ltd. was officially registered on May 30, 2025 [1] - The hospital's operating income and net profit will be consolidated into Yingkang Life's financial statements [1] - The financial impact of the hospital's performance has been reported in the company's semi-annual report [1]